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months of the index date including the index date (cohort
Cnn), patients with no CHF but MI or stroke (cohort Cny),
patients with CHF but no MI or stroke (cohort Cyn), and
patients with both CHF and MI or stroke (cohort Cyy).
RESULTS: Number of patients identified for cohorts Cnn,
Cny, Cyn and Cyy were 319, 91, 195 and 59; among them
52%, 41%, 52%, and 47% were female, respectively.
The mean ages of patients in cohorts Cnn, Cny, Cyn and Cyy
were 68.5, 73.5, 75.2, and 76, respectively. The follow-
ing table shows the hospital utilization (percent of AF/F
patients hospitalized for any reason):
CONCLUSIONS: Cost intensive resource utilization, such
as hospitalization, increases up to 139.3% after the diag-
nosis of AF/F as recorded in a managed care claims data-
base. Although patients with concomitant illnesses, such
as CHF, MI, and stroke, have higher hospital utilization
compared to patients without such diseases, AF/F con-
tributes to the highest percentage increase for the healthi-
est patient population.
PCV9
COST-COMPARISON ANALYSIS OF HOME-
MONITORING AND AMBULANT MONITORING 
OF ORAL ANTICOAGULATION
IN SWITZERLAND
Neeser K, Weiss C, Brandt A, Palmer AJ
IMIB, Institute for Medical Informatics and Biostatistics, Basel, 
Switzerland
BACKGROUND: A disease model was developed to com-
pare clinical and economic outcomes of home monitoring
versus ambulant monitoring in anticoagulation patients
with heart valve implants in two different locations. The
improved outcomes seen with home monitoring result from
tighter control of the anticoagulation (AC) level. Thereby a
higher proportion of patients is kept within the therapeutic
INR target range leading to a decreased incidence of ad-
verse events.
OBJECTIVE: The model compares the event-rates of ma-
jor thromboembolic events (TE), major bleeding (BL) com-
plications and mortality rates in cohorts with mechanical
heart valve replacement requiring oral anticoagulation with
warfarin.
METHODS: The AC monitoring strategies compared
were A) 52 times/year home monitoring of AC with the
CoaguChek home-monitor, and B) monthly monitoring
in an outpatient clinic (with laboratory tested AC levels).
Direct costs of basic treatment, patient education and mon-
itoring, as well as treatment costs of complications were
collected from the Swiss third party payer perspective. Com-
plication rates (TE, BL, mortality) were derived from pub-
lished literature and official agency reports. The health eco-
nomic analysis simulated an observational time of 10 years.
Cost outcomes were discounted at a real annual rate of 5%.
RESULTS: Self-monitoring by patients reduces the total
costs (monitoring and complication related costs) per pa-
tient from Swiss Francs (CHF) 8’988 to CHF 7’532 per pa-
tient over the observation time of 10 years. Sensitivity anal-
ysis were performed and identified the main cost drivers as:
frequency of home monitoring, cost per home monitoring
test, cost and durability of home monitoring device.
CONCLUSION: Demonstrated within the limitations of
the modelling approach, the application of home monitor-
ing in heart valve implant patients is dominant to ambulant
monitoring in outpatient clinics, with increased life quality
and decreased overall costs.
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BACKGROUND: High serum lipid levels are an impor-
tant risk factor for cardiovascular disease such as myocar-
dial infarction and stroke. Recently, an American study
demonstrated that 5 years after beginning treatment, ap-
proximately half of the cohort studied had stopped statin
therapy.1 The aim of our study was to estimate adherence
to statins in Tayside and to determine if co-morbidity, so-
cial deprivation, and co-prescribing were predictors of ad-
herence.
METHODS: Two studies were performed: Study 1, to de-
termine adherence to statins over a 5-year period of follow-
up and predictors of that adherence. Study 2, to find pre-
dictors of compliance with statins in a 13-month follow-up
period after publication of the 4S-study.2 The study popula-
tion consisted of all individuals from the fixed population
base who received more than one prescription for a statin.
For each individual, adherence to therapy was defined as
the days for which statins had been dispensed divided by
the number of days they should have been dispensed. Peo-
ple who had statins dispensed for 85% or more of their
days in the community were classified as adherent. Logistic
regression analyses were performed to determine predictors
of short-term and long-term adherence.
RESULTS: Study 1. After 5 years, 65% of the original co-
hort (n  392) were still collecting prescriptions for statins.
89 (23%) were adherent to statin therapy. Predictors of
adherence were cardiovascular disease (OR: 1.19), female
gender (OR 1.67), and co-prescribing of nitrates (OR
1.62). Study 2. Of the 1548 people who received a statin,
652 (42%) were adherent to therapy. In this study, predic-
tors were age (OR 1.02), use of nitrates (OR 0.76), and di-
abetes (OR 0.65).
Cnn Cny Cyn Cyy Total
Before index date 13.5 35.2 33.9 47.5 25.5
After index date 32.3 42.9 57.4 54.2 43.1
Percent increase 139.3 21.9 69.3 14.1 69.0
